Literature DB >> 26946218

Operational Characteristics of Linear Concentration-QT Models for Assessing QTc Interval in the Thorough QT and Phase I Clinical Studies.

C Garnett1, K Needleman2, J Liu3, R Brundage4, Y Wang3.   

Abstract

Concentration-QTc (C-QTc) analysis can be used as an alternative to the standard statistical methods in clinical QT studies. Pharmacokinetic/pharmacodynamics (PK/PD) simulations were performed to assess the operating characteristics of four C-QTc models. False negatives were 2-6% for crossover and 2-9% for parallel studies, with 12 to 60 subjects per treatment for a dose with 10-ms mean effect. All C-QTc models tested gave less than +1 ms mean bias in the ΔΔQTcmax prediction. The power to exclude 10 ms was >80% across all study designs and sizes, for a dose with 3-ms mean effect. The study demonstrates that linear C-QTc models have adequate sensitivity and specificity when the simulation and data analytical models are the same. C-QTc models that incorporate time- and treatment-specific terms give the least biased ΔΔQTcmax predictions under scenarios of model-misspecifications and offer an advantage when applying to real clinical data where the underlying relationship is not known.
© 2016 The American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26946218     DOI: 10.1002/cpt.361

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

Review 1.  Scientific white paper on concentration-QTc modeling.

Authors:  Christine Garnett; Peter L Bonate; Qianyu Dang; Georg Ferber; Dalong Huang; Jiang Liu; Devan Mehrotra; Steve Riley; Philip Sager; Christoffer Tornoe; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-05       Impact factor: 2.745

2.  Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods.

Authors:  Jingtao Lu; Jianguo Li; Gabriel Helmlinger; Nidal Al-Huniti
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-19       Impact factor: 2.745

3.  Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers.

Authors:  Junzhen Wu; Guoying Cao; Hailan Wu; Yuancheng Chen; Beining Guo; Xiaojie Wu; Jicheng Yu; Kanhong Ni; Jin Qian; Li Wang; Jufang Wu; Yu Wang; Hong Yuan; Jing Zhang; Yuewen Xi
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

4.  Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure-response analysis.

Authors:  Nikolaos Tsamandouras; Sridhar Duvvuri; Steve Riley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-10-29       Impact factor: 2.745

5.  Concentration-QTc analysis with two or more correlated baselines.

Authors:  Yasushi Orihashi; Yuji Kumagai
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-05-12       Impact factor: 2.745

6.  Concentration-QTc analysis for single arm studies.

Authors:  Yasushi Orihashi; Shoichi Ohwada; Yuji Kumagai
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-01-29       Impact factor: 2.745

7.  Detection and impact of hysteresis when evaluating a drug's QTc effect using concentration-QTc analysis.

Authors:  Georg Ferber; Borje Darpo; Christine Garnett; Dalong Huang; Dhananjay D Marathe; Yaning Sun; Jiang Liu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-28       Impact factor: 2.745

8.  Estimation of the Power of the Food Effect on QTc to Show Assay Sensitivity.

Authors:  Georg Ferber; Sara Fernandes; Jörg Täubel
Journal:  J Clin Pharmacol       Date:  2017-08-17       Impact factor: 3.126

9.  PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.

Authors:  Andrea Henrich; Pierre-Eric Juif; Jasper Dingemanse; Andreas Krause
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-01-02       Impact factor: 2.745

Review 10.  Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation Study.

Authors:  Jose Vicente; Robbert Zusterzeel; Lars Johannesen; Jay Mason; Philip Sager; Vikram Patel; Murali K Matta; Zhihua Li; Jiang Liu; Christine Garnett; Norman Stockbridge; Issam Zineh; David G Strauss
Journal:  Clin Pharmacol Ther       Date:  2017-11-16       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.